Top

Published in:

01-06-2011 | Original Article

Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life

Authors: Alberto Raggi, Matilde Leonardi, Gennaro Bussone, Domenico D’Amico

Published in: Neurological Sciences | Issue 3/2011

Abstract

The aim of this paper is to explore the relationships between health-related quality of life (HRQoL), assessed with the Short Form-36 (SF-36), and disability in adult migraineurs using both disease-specific and generic tools, the WHO Disability Assessment Schedule II (WHO-DAS II) and with the Migraine Disability Assessment questionnaire (MIDAS). Significant differences were observed between patients with minimal/mild and moderate/severe MIDAS disability grades for Role Physical, Bodily Pain, General Health, Vitality, Social Functioning and Physical Composite Score of the SF-36; in the WHO-DAS II for household activities, participation in society and for summary score. WHO-DAS II and MIDAS provide complementary information on the intensity and the frequency of problems in performing daily activities, and could be used jointly. Our findings indicate that these issues are relevant for patients’ health status and should be taken into account in future research on migraine as important secondary outcomes of treatment interventions.

Freitag F (2007) The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther 29:939–949PubMedCrossRef

Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23:441–450PubMedCrossRef

Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210PubMedCrossRef

Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D (2004) Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 25:S105–S107PubMedCrossRef

Murray CJL, Lopez AD, Mathers CD, Stein C (2000) WHO Burden Series paper 36: The Global Burden of Disease 2000 project: aims, methods and data sources. WHO, Geneva

World Health Organization (2001) The World Health Report 2001: Mental health, new understanding new hope. WHO, Geneva

Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12:S1–S27CrossRef

Berg J, Stovner LJ (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12:S59–S62CrossRef

Massetto N, Gambini C, Bernardoni P, Ferrante E, Lovati C, Moschiano F, Tonini MC, Bussone G, D’Amico D (2009) Underdiagnosis of primary headaches: results of a survey on patients attending headache centres. Neurol Sci 30:S129–S131PubMedCrossRef

10.

Lipton RB, Stewart WF (1993) Migraine in the United States: a review of epidemiology and health care use. Neurology 43:6–10

11.

Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, on behalf of the AEGIS Investigator Study Group (2008) Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS trial. Headache 48:341–354PubMedCrossRef

12.

D’Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani F, De Marco R, Massetto N, Bussone G, Progetto Cefalee Lombardia Group (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691–696PubMedCrossRef

13.

Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L (2007) The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 5:56PubMedCrossRef

14.

Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 40:204–215PubMedCrossRef

15.

Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD (1995) Validation of a new quality of life questionnaire for acute migraine headache. Headache 35:330–337PubMedCrossRef

16.

Ware JE (2000) SF-36 health survey update. Spine 25:3130–3139PubMedCrossRef

17.

Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19:1–96CrossRef

18.

World Health Organization (2001) The international classification of functioning, disability and health-ICF. WHO, Geneva

19.

Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Del Río MS, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062PubMedCrossRef

20.

Fuh JL, Wang SJ (2006) Comparison of Short Form-36 and migraine disability assessment questionnaire in patients with migraine. Clin J Pain 22:564–568PubMedCrossRef

21.

D’Amico D, Usai S, Solari A, Grazzi L, Leone M, Rigamonti A, Bussone G (2003) Relationship between disability and quality of life in migraine. In: Olesen J, Steiner TS, Lipton RB (eds) Reducing the burden of headache. Oxford University Press, New York, pp 75–78

22.

Raggi A, Leonardi M, Ajovalasit D, D’Amico D, Bussone G (2010) Disability and functional profiles of patients with migraine measured with ICF classification. Int J Rehabil Res 32:225–231

23.

Ustun TB (1999) WHO-DAS II field trials report 1998. WHO, Geneva

24.

Cankurtaran ES, Ulug B, Saygi S, Tiryaki A, Akalan N (2005) Psychiatric morbidity, quality of life, and disability in mesial temporal lobe epilepsy patients before and after anterior temporal lobectomy. Epilepsy Behav 7:116–122PubMedCrossRef

25.

Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, Malucelli E, Manners D, Kemp GJ, Testa C, Barbiroli B, Lodi R (2008) Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle’s disease. Muscle Nerve 37:350–357PubMedCrossRef

26.

Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R (2010) The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol 257:98–102PubMedCrossRef

27.

Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R (2010) Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurol Sci 31:41–45PubMedCrossRef

28.

Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24:S1–S160

29.

D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G (2001) The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 21:947–952PubMedCrossRef

30.

Federici S, Meloni F, Mancini A, Lauriola M, Olivetti Belardinelli M (2009) World Health Organisation Disability Assessment Schedule II: contribution to the Italian validation. Disabil Rehabil 31:553–564PubMedCrossRef

31.

Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036PubMedCrossRef

32.

Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988–994PubMed

33.

Silberstein SD, Loder E, Forde G, Papadopulos G, Fairclough D, Greenberg S (2006) The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 22:1021–1029PubMedCrossRef

34.

Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50–S58PubMedCrossRef

Title: Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life
Authors: Alberto Raggi
Matilde Leonardi
Gennaro Bussone
Domenico D’Amico
Publication date: 01-06-2011
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 3/2011
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-010-0466-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Alien hand syndrome in left posterior stroke

Botulinum toxin type A: an effective treatment to restore phonation in laryngectomized patients unable to voice

Temporal coincidence of myasthenia gravis and Guillain Barré syndrome associated with Hashimoto thyroiditis

A case of carotid body paraganglioma and haemangioblastoma of the spinal cord in a patient with the N131K missense mutation in the VHL gene

Quality of life in multiple sclerosis patients with urinary disorders: reliability and validity of the Turkish version of King’s Health Questionnaire

Serotonin toxicity: a short review of the literature and two case reports involving Citalopram